Jade Biosciences, Inc. (JBIO) Dividend History

Jade Biosciences, Inc. (JBIO) is a biotechnology company focused on developing innovative solutions in the fields of cell therapy and regenerative medicine. The company leverages advanced biotechnologies to create therapeutic products aimed at improving patient outcomes in various medical conditions. Through research and development, Jade Biosciences seeks to advance treatment options by combining scientific innovation with clinical applications.

Dividend History

Jade Biosciences, Inc. currently does not pay dividends

Company News

  • Jade Biosciences will participate in two upcoming investor conferences, with CEO Tom Frohlich and CSO Andrew King presenting their lead candidate JADE101 for immunoglobulin A nephropathy treatment, with first-in-human clinical trials expected in the second half of 2025.

    GlobeNewswire Inc.
Page data last updated 08/19/2025 16:51:46 UTC